Page 2 - புற்றுநோயியல் இல் பென் பெரல்மேன் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from புற்றுநோயியல் இல் பென் பெரல்மேன் பள்ளி ஆஃப் மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In புற்றுநோயியல் இல் பென் பெரல்மேன் பள்ளி ஆஃப் மருந்து Today - Breaking & Trending Today

New Biomarker May Predict Which Pancreatic Cancer Patients Respond to CD40 Immunotherapy

Date Time
New Biomarker May Predict Which Pancreatic Cancer Patients Respond to CD40 Immunotherapy
PHILADELPHA-Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won’t respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.
It is known that pancreatic cancer can cause systemic inflammation, which is readily detectable in the blood. The team found that patients with systemic inflammation had worse overall survival rates than patients without inflammation when treated with both a CD40 agonist and the chemotherapy gemcitabine. ....

United States , Michaela Giannone , Maxm Wattenberg , Veronicam Herrera , Gregoryl Beatty , Whitneyl Gladney , National Institutes Of Health , Perelman School Of Medicine , Abramson Cancer Center , Oncology At Penn Perelman School Of Medicine , Robertl Fine Cancer Research Foundation , Penn Pancreatic Cancer Research Center , University Of Pennsylvania , Perelman School , National Institutes , Cancer Research , ஒன்றுபட்டது மாநிலங்களில் , மைக்கேலா ஜியானோன் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , பெரல்மேன் பள்ளி ஆஃப் மருந்து , புற்றுநோயியல் இல் பென் பெரல்மேன் பள்ளி ஆஃப் மருந்து , பென் கணையம் புற்றுநோய் ஆராய்ச்சி மையம் , பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா , பெரல்மேன் பள்ளி , தேசிய நிறுவனங்கள் , புற்றுநோய் ஆராய்ச்சி ,

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

Share this article
Share this article
PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA s total capital raised to nearly $109 million. The funding will be used to advance current pipeline and discovery programs, including the Phase I clinical trial of CARISMA s lead candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M), which recently initiated trial enrollment and patient screening for the first-of-its-kind, first-in-human study of CAR-M. The funding will also allow CARISMA to further develop its proprietary engineered-macrophage platform, continue pipeline expansion in cancer indications and enable the platform s application to disease areas outside of ca ....

University Of Pennsylvania , United States , New Zealand General , New Zealand , Saar Gill , Michael Klichinsky , Steven Kelly , Christina Khoury Folkens , University Of North Carolina , Perelman School Of Medicine , Abramson Cancer Center , Livzon Pharmaceutical Group Inc , Therapeutics Inc , Ip Group , Ventures Fund , Oncology In Penn Perelman School Of Medicine , Solasta Ventures , Livzon Pharmaceutical Group , Abbvie Ventures , Wellington Partners , Agent Capital , Chief Executive Officer , Chimeric Antigen Receptor Macrophages , Nature Biotechnology , Scientific Co Founder , Vice President ,